Sionna Therapeutics, Inc. (SION)Healthcare | Biotechnology | Waltham, United States | NasdaqGM
42.64 USD
-0.90
(-2.067%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:03 a.m. EDT
Technical momentum is breaking out of a 200-day consolidation ($32-$37), driven by a speculative 'Moderate Buy' consensus and a stark lack of put protection at current levels, indicating a high-conviction 43% short-term upside target ($47-52) based on technicals and options gamma, despite a weak fundamental outlook for the next multi-year horizon. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.123035 |
| AutoETS | 0.133317 |
| AutoARIMA | 0.133909 |
| AutoTheta | 0.213488 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.86 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.214 |
| Excess Kurtosis | -0.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.828 |
| Market Cap | 1,918,717,824 |
| Forward P/E | -16.52 |
| Website | https://www.sionnatx.com |
As of April 19, 2026, 12:03 a.m. EDT: Options flow is highly asymmetric with overwhelming call gamma exposure at near-term strikes (near term OTM OI heavily skewed to calls,olim practice. In the short term (Apr 17), there is minimal positioning, but May-July expirations show significant call Open Interest (OI) building at $45-$50 strikes (ATM/Monitoring $55). Conversely, put OI beyond July fades significantly after 2026-10-16, with defensive puts for 2026-01-06. The weak put positioning relative to the price target range suggests bullish speculation is the primary sentiment.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.5741827 |
| Address1 | 21 Hickory Drive |
| Address2 | Suite 500 |
| All Time High | 46.458 |
| All Time Low | 7.255 |
| Ask | 42.99 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 504,930 |
| Average Daily Volume3 Month | 336,904 |
| Average Volume | 336,904 |
| Average Volume10Days | 504,930 |
| Bid | 42.26 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 6.861 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 42.64 |
| Current Ratio | 20.613 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 44.69 |
| Day Low | 41.98 |
| Debt To Equity | 2.828 |
| Display Name | Sionna Therapeutics |
| Earnings Timestamp | 1,772,458,200 |
| Earnings Timestamp End | 1,777,984,200 |
| Earnings Timestamp Start | 1,777,984,200 |
| Ebitda | -88,335,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -19.149 |
| Enterprise Value | 1,691,512,832 |
| Eps Current Year | -2.20875 |
| Eps Forward | -2.58143 |
| Eps Trailing Twelve Months | -1.88 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 37.7589 |
| Fifty Day Average Change | 4.8810997 |
| Fifty Day Average Change Percent | 0.12927018 |
| Fifty Two Week Change Percent | 257.41827 |
| Fifty Two Week High | 46.458 |
| Fifty Two Week High Change | -3.8180008 |
| Fifty Two Week High Change Percent | -0.082181774 |
| Fifty Two Week Low | 10.965 |
| Fifty Two Week Low Change | 31.675 |
| Fifty Two Week Low Change Percent | 2.8887367 |
| Fifty Two Week Range | 10.965 - 46.458 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,738,938,600,000 |
| Float Shares | 15,784,424 |
| Forward Eps | -2.58143 |
| Forward P E | -16.517977 |
| Free Cashflow | -44,264,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 59 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.068720005 |
| Held Percent Institutions | 0.97019994 |
| Implied Shares Outstanding | 44,998,073 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-02-07 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts. |
| Long Name | Sionna Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,918,717,824 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1779769831 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -75,268,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,926,817,485 |
| Number Of Analyst Opinions | 9 |
| Open | 43.54 |
| Operating Cashflow | -66,297,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 819 2020 |
| Pre Market Change | 0.15999985 |
| Pre Market Change Percent | 0.37523416 |
| Pre Market Price | 42.8 |
| Pre Market Time | 1,776,771,324 |
| Previous Close | 43.54 |
| Price Eps Current Year | -19.305037 |
| Price Hint | 2 |
| Price To Book | 6.2148376 |
| Profit Margins | 0.0 |
| Quick Ratio | 20.14 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | -0.900002 |
| Regular Market Change Percent | -2.06707 |
| Regular Market Day High | 44.69 |
| Regular Market Day Low | 41.98 |
| Regular Market Day Range | 41.98 - 44.69 |
| Regular Market Open | 43.54 |
| Regular Market Previous Close | 43.54 |
| Regular Market Price | 42.64 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 446,869 |
| Return On Assets | -0.21736999 |
| Return On Equity | -0.31792998 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 44,998,073 |
| Shares Percent Shares Out | 0.083500005 |
| Shares Short | 3,756,705 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,350,255 |
| Short Name | Sionna Therapeutics, Inc. |
| Short Percent Of Float | 0.1385 |
| Short Ratio | 11.9 |
| Source Interval | 15 |
| State | MA |
| Symbol | SION |
| Target High Price | 63.0 |
| Target Low Price | 24.0 |
| Target Mean Price | 49.11111 |
| Target Median Price | 52.0 |
| Total Cash | 235,882,000 |
| Total Cash Per Share | 5.242 |
| Total Debt | 8,677,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.88 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 33.1963 |
| Two Hundred Day Average Change | 9.443699 |
| Two Hundred Day Average Change Percent | 0.28448045 |
| Type Disp | Equity |
| Volume | 446,869 |
| Website | https://www.sionnatx.com |
| Zip | 2,451 |